Interleukin-2 gene therapy - Valentis

Drug Profile

Interleukin-2 gene therapy - Valentis

Alternative Names: IL-2 genemedicine; Interleukin-2 genemedicine; VLTS-587

Latest Information Update: 25 Jan 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Valentis
  • Class Antineoplastics; Cytokine genes; Gene therapies; Interleukins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Head and neck cancer; Lung cancer; Malignant melanoma

Most Recent Events

  • 24 Jan 2017 Discontinued - Phase-I for Lung cancer in USA (IV)
  • 24 Jan 2017 Discontinued - Phase-II for Head and neck cancer in Russia, Germany, Czech Republic (Intratumoural)
  • 24 Jan 2017 Discontinued - Phase-II for Malignant melanoma in USA (Intratumoural)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top